| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CGEM | Common Stock | Options Exercise | $17.2K | +4K | +17.46% | $4.30 | 26.9K | Aug 18, 2021 | Direct | |
| transaction | CGEM | Common Stock | Sale | -$78.7K | -2.86K | -10.64% | $27.50 | 24K | Aug 18, 2021 | Direct | F1, F2 |
| transaction | CGEM | Common Stock | Sale | -$31.9K | -1.14K | -4.73% | $28.07 | 22.9K | Aug 18, 2021 | Direct | F1, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CGEM | Stock Option (Right to Buy) | Options Exercise | $0 | -4K | -1.74% | $0.00 | 226K | Aug 18, 2021 | Common Stock | 4K | $4.30 | Direct | F4 |
| Id | Content |
|---|---|
| F1 | Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021. |
| F2 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.91 to $27.89. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| F3 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $27.92 to $28.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| F4 | 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Chief Development Officer, Biologics This amended Form 4 is being filed to include an explanatory note that the reported sales were made pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021.